The Danish National Prescription Registry

Kildemoes, Helle Wallach; Sørensen, Henrik Toft; Hallas, Jesper

doi:10.1177/1403494810394717

Cited by 2,050 publications

(929 citation statements)

References 9 publications

Supporting

Mentioning

925

Contrasting

Order By: Relevance

“…The registry also holds information on surgical procedures according to the NOMESCO classification 7. The National Prescription Registry includes information on prescription drugs in terms of strength, number of tablets, and date of prescription according to Anatomical Therapeutical Classification codes 8. The Civil Personal Registry holds information on vital status, sex, and age 9.…”

Section: Methodsmentioning

confidence: 99%

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients

Lamberts

Stærk

Olesen

et al. 2017

JAHA

123

121

View full text Add to dashboard Cite

BackgroundThe nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding risk, are lacking. Our objective was to compare major bleeding events and nonpersistence between the nonvitamin K antagonist oral anticoagulant apixaban and other nonvitamin K antagonist oral anticoagulants (dabigatran and rivaroxaban) and warfarin in a contemporary, nation‐wide cohort of patients with nonvalvular atrial fibrillation.Methods and ResultsOf 54 321 patients (median age, 73 years; 56% male; mean CHA 2 DS 2‐VASc score, 2.9), 7963, 6715, 15 413, and 24 230 patients initiated apixaban, rivaroxaban, dabigatran, and warfarin, respectively. Apixaban and rivaroxaban initiators were older, less often male, with higher HAS‐BLED and CHA 2 DS 2‐VASc scores compared with dabigatran and warfarin initiators. A total of 2418 patients (4.5%) experienced a major bleeding event over all available follow‐up. In this period, rivaroxaban (hazard ratio [HR] [95% CI], 1.49 [1.27–1.77]), dabigatran (HR, 1.17 [1.00–1.38]), and warfarin (HR, 1.23 [1.05–1.43]) users were significantly more likely to bleed than apixaban users. Findings were similar when restricted to the first 30 days after OAC initiation. Risk of nonpersistence was higher for dabigatran (HR, 1.45 [1.33–1.59]) and warfarin initiators (HR, 1.22 [1.12–1.33]), but not for rivaroxaban initiators (HR, 1.07 [0.96–1.20]) compared with apixaban initiators.ConclusionsIn a real‐world cohort of nonvalvular atrial fibrillation patients, apixaban had a lower adjusted major bleeding risk compared with rivaroxaban, dabigatran, and warfarin. Apixaban had a lower risk of nonpersistence compared with dabigatran and warfarin and similar risk compared with rivaroxaban.

show abstract

Section: Methodsmentioning

confidence: 99%

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients

Lamberts

Stærk

Olesen

et al. 2017

JAHA

123

121

View full text Add to dashboard Cite

show abstract

“…All prescriptions dispensed from Danish pharmacies are registered in the Danish Registry of Medicinal Product Statistics according to the Therapeutical Chemical system. 9 The Danish Civil Registration System keeps information on vital status and cause of death for every citizen. 10 The Danish Registry on Regular Dialysis and Transplantation holds complete and valid information on all Danish citizens treated with chronic renal replacement therapy.…”

Section: Study Settingmentioning

confidence: 99%

Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation

Bonde

Lip

Kamper

et al. 2016

Stroke

View full text Add to dashboard Cite

Background and Purpose— We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. Methods— We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. Results— A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97–1.56), 1.26 (95% CI, 1.14–1.40), 1.18 (95% CI, 1.07–1.31), 1.11 (95% CI, 0.87–1.42), 2.01 (95% CI, 1.14–3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m 2 , respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m 2 ; hazard ratios 0.57 (95% CI, 0.43–0.76), 0.57 (95% CI, 0.51–0.64), 0.48 (95% CI, 0.44–0.54), 0.60 (95% CI, 0.45–0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m 2 , respectively. Use of warfarin was not associated with lower risk of stroke/thromboembolism in patients with eGFR<15 mL/min per 1.73 m 2 ; hazard ratio 1.18 (95% CI, 0.58–2.40). Conclusions— In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m 2 .

show abstract

“…The Danish Prescription Registry contains data on all prescription drugs dispensed to Danish residents since 1995 (Kildemoes et al. 2011). The data include the type of drug, date of dispensing and quantity dispensed.…”

Section: Methodsmentioning

confidence: 99%

“…Drugs are categorized according to the Anatomical Therapeutic Chemical Index (Kildemoes et al. 2011). The Danish National Patient Register contains nationwide data on all non‐psychiatric hospital admissions since 1977 and all outpatient specialist contacts in hospital setting since 1995 (Schmidt et al.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Ophthalmic nepafenac use in the Netherlands and Denmark

Margulis¹,

Houben

Hallas

et al. 2017

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

PurposeTo describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac.MethodsWe identified users in the PHARMO Database Network (the Netherlands, 2008–2013) and the Danish national health registers (Denmark, 1994–2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes.ResultsIn the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery. Of 2266 episodes in adult non‐diabetic patients with cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days). Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to two bottles dispensed (≤60 days).Denmark had 60 403 nepafenac users (mean age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract surgery). Of 26 649 nepafenac episodes in adult non‐diabetic patients with cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult diabetic patients with cataract surgery, 99.8% had up to two bottles dispensed.Use patterns of nepafenac, ketorolac and diclofenac were roughly similar in the Netherlands, but not in Denmark.ConclusionLess than half of therapy episodes were related to cataract surgery; around 90% of episodes with surgery were within the approved duration. Underrecording of ophthalmic conditions and procedures was a challenge in this study.

show abstract

The Danish National Prescription Registry

Cited by 2,050 publications

References 9 publications

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients

Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation

Ophthalmic nepafenac use in the Netherlands and Denmark

Contact Info

Product

Resources

About